You are here

Trans‐nasal delivery of chemotherapy to glioblastoma using magnetic nanoparticles and magnetic focusing

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA213540-01A1
Agency Tracking Number: R41CA213540
Amount: $142,262.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA16-303
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-06-01
Award End Date (Contract End Date): 2019-05-31
Small Business Information
5611 ROOSEVELT ST
Bethesda, MD 20817-6739
United States
DUNS: 809594661
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 STEVEN TOMS
 (216) 312-4992
 tomsstn1964@gmail.com
Business Contact
 IRVING WEINBERG
Phone: (301) 346-7944
Email: inweinberg@gmail.com
Research Institution
 RHODE ISLAND HOSPITAL
 
593 EDDY STREET
PROVIDENCE, RI 02903-4923
United States

 Domestic nonprofit research organization
Abstract

Abstract
Glioblastoma multiforme GBM is the deadliest form of brain tumor The current treatment includes
a combination of surgical resection chemotherapy radiation and electrical disruption of mitosis has
only extended survival to approximately to years Preliminary pre clinical findings suggest the
potential effectiveness of the candidate drug cyclopamine However the drug is toxic to systemic stem
cells when given intravenously and at high concentrations in the nervous system may cause toxicity to
astrocytes Furthermore poor solubility has precluded effective transport of drug to tumor in the
central nervous system
The Molecular Neurosurgery Laboratory led by the STTR PI neurosurgeon Dr Steven Toms at the
Geisinger Medical Center has expertise in nanoparticulate delivery to brain tumors and has developed
a human glioblastoma stem cell derived xenograft model for in vitro and in vivo testing of therapies for
GBM
STTR applicant Weinberg Medical Physics LLC has developed a new method of transporting drug
across the blood brain barrier directly to target sites within the brain This approach accesses the brain
via administration of magnetically propelled nanoparticles into the cranium with magnetic focusing of
the drug laden nanoparticles in a novel combined MR imaging magnetic focusing apparatus
In this proposal we will demonstrate the safety and efficacy of drug delivery of the magnetic
nanoparticle cyclopamine construct using the MR imaging magnetic focusing apparatus by measuring
cyclopamine drug concentrations in animal tissues In addition we will confirm that there are no
neuropathological changes to the animals as a result of the magnetic propulsion process and
demonstrate that this method of drug delivery improves survival in rodent GBM xenograft models The
results of this collaborative work will lay the foundation for Phase II studies that will collect information
needed for clinical trials STTR applicant Weinberg Medical Physics LLC has developed a new method of
transporting drug across the blood brain barrier directly to target sites within the brain
This approach accesses the brain via trans nasal administration of magnetically
propelled nanoparticles and then magnetically focuses the drug laden nanoparticles in a
novel combined MR imaging magnetic focusing apparatus In this proposal we will
demonstrate the safety and efficacy of drug delivery of the magnetic
nanoparticle cyclopamine construct using the MR imaging magnetic focusing apparatus
by measuring cyclopamine drug concentrations in animal tissues

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government